Combination Immunotherapy Strategies for Melanoma in the Adjuvant Setting

EP: 1.An Overview of the Landscape Surrounding Melanoma

EP: 2.The Role of Biomarker Testing in Melanoma

EP: 3.The Current Landscape Surrounding Adjuvant Therapy in Melanoma

Now Viewing

EP: 4.Combination Immunotherapy Strategies for Melanoma in the Adjuvant Setting

EP: 5.Navigating Challenges in Predicting and Mitigating Adverse Events in Adjuvant Immunotherapy

EP: 6.Exploring Immunotherapy Resistance: Impact on Treatment Decisions in Melanoma

EP: 7.Balancing Quality of Life: Adjuvant Therapy Toxicity in Melanoma Adjuvant Immunotherapy

EP: 8.Case 1: Man Aged 55 Years With Stage IIIB Melanoma Developing Immunotherapy-Induced Diabetes

EP: 9.Immunotherapy-Related Diabetes in Melanoma: A Management Perspective

EP: 10.Immunotherapy-Induced Adrenal Insufficiency in Melanoma: Surveillance and Management

EP: 11.Case 2: 63-Year-Old Female Patient With Metastatic Melanoma on Dual Immunotherapy Developing Treatment-Related Myocarditis

EP: 12.Approaches to Diagnosing and Managing Myocarditis Related to Immunotherapy

EP: 13.Expert Perspectives on Cardiac Baseline and Surveillance Testing in Immunotherapy Recipients

EP: 14.Corticosteroid Treatment Challenges in Patients with Immunotherapy-Related Toxicities

EP: 15.Forward Outlook and Clinical Insights in Melanoma Treatment

This is a video synopsis/summary of an OncLive Insights^® discussion involving Afreen Shariff, MD, MBBS; Javid Moslehi, MD; and Nikhil Khushalani, MD.

This segment focuses on deciding between monotherapy versus dual immunotherapy approaches in melanoma. Dr Khushalani states that based on the negative data from the CheckMate 915 trial, there is currently no role for adjuvant doublet immunotherapy with anti–PD-1 plus anti–CTLA-4 inhibition for patients with resected stage III disease. The one exception is patients with resected stage IV disease, who have very high recurrence risk even after surgery. Data from an IMMUNED in these patients showed improved relapse-free and overall survival with the adjuvant ipilimumab/nivolumab combination versus nivolumab alone or observation. Thus, Dr Khushalani will discuss adjuvant ipilimumab and nivolumab as an option for patients with resected stage IV disease, considering modified dosing to mitigate toxicity risks. The efficacy of neoadjuvant nivolumab plus relatlimab (LAG-3 pathway inhibitor) is still unknown pending trial results.

Video synopsis is AI-generated and reviewed by OncLive® editorial staff.